KRAS and cancer: To evaluate the impact of the Affimer proteins on MAPK signaling in the presence of mutant, oncogenic forms of KRAS, the following cancer cell lines were utilized: Panc 10.05 (KRASG12D), SW620 (KRASG12V), and NCI-H460 (KRASQ61H).